FDG-PET/CT was available in 22 (11 breast adenocarcinoma, 5 lymphoma, 3 mucinous gastrointestinal cancer, 2 prostate adenocarcinoma, 1 transitional cell cancer), PSMA-PET/CT in two (prostate adenocarcinoma), and Choline-PET/CT in three (prostate adenocarcinoma) patients within four months prior to biopsy. The gene discussed is FOLH1; the disease is prostate adenocarcinoma.